天津科学技术出版社

多技术与策略整合驱动的细胞治疗产品非临床药代动力学研究进展

魏喆 #,刘欣欣 #,杜文静 *
作者信息
  1.  天津市细胞制药工程技术重点实验室,细胞产品国家工程研究中心,天津昂赛细胞基因工程有限公司,天津 300457
#共同第一作者
*通信作者

摘要

细胞治疗产品(CTPs)作为再生医学与精准医疗的核心策略,在多种难治性疾病中展现出巨大应用潜力。 鉴于其“活体药物”的独特属性,CTPs 的非临床药代动力学(PK)研究面临体内动态行为复杂、示踪分析困难等独特挑战。本文以嵌合抗原受体T细胞(CAR-T)和间充质干/ 基质细胞(MSCs)为代表性案例,系统综述CTPs的非临床PK特征及其关键影响因素,深入剖析当前 PK 研究中的先进检测技术与生物模型选择策略,并从监管科学角度阐述现行法规对非临床 PK 研究的具体要求,进而整合分析提出该领域面临的核心挑战,旨在为 CTPs 的非临床研发与评价提供系统性技术参考,以促进其向临床更安全、更有效地转化应用。

Progress in integrated technologies and strategies driving advances in nonclinical pharmacokinetics of cell therapy products

Zhe WEI #, Xinxin LIU #, Wenjing DU *
Author Information
  1.  Tianjin Key Laboratory of Engineering Technologies for Cell Pharmaceuticals, National Engineering Research Center of Cell Products, AmCellGene Co. , Ltd. , Tianjin 300457, China
#Co-first author
*Corresponding author

Abstract

Cell therapy products (CTPs), as a core strategy in regenerative and precision medicine, demonstrate tremendous potential for various refractory diseases. Given their unique"living drug" attributes, nonclinical pharmacokinetic (PK) studies of cell therapy products face distinct challenges, including complex in vivo dynamics and difficult tracking analysis. Using chimeric antigen receptor T cells (CAR-T) and mesenchymal stem/ stromal cells (MSCs) as representative cases, this review systematically summarizes the nonclinical PK characteristics and key determinants of cell therapy products, provides in-depth analysis of advanced detection technologies and biological model selection strategies in current PK research, delineates specific regulatory requirements for nonclinical PK studies from a regulatory science perspective, and subsequently synthesizes the core challenges confronting this field. This review aims to provide systematic technical references for the nonclinical development and evaluation of cell therapy products, thereby facilitating their safer and more effective clinical translation.

再生医学研究 Copyright © 2026. All Rights Reserved